Welcome
Support Centre
21 March 2013 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
A randomised trial of epirubicin and cyclophosphamide versus epirubicin and paclitaxel in the treatment of women with metastatic breast cancer
ISRCTN ISRCTN75147488
DOI 10.1186/ISRCTN75147488
ClinicalTrials.gov identifier NCT00002953
EudraCT number
Public title A randomised trial of epirubicin and cyclophosphamide versus epirubicin and paclitaxel in the treatment of women with metastatic breast cancer
Scientific title
Acronym N/A
Serial number at source AB01
Study hypothesis To compare epirubicin and paclitaxel versus epirubicin and cyclophosphamide in metastatic breast cancer
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment South Africa, United Kingdom
Disease/condition/study domain Cancer
Participants - inclusion criteria 1. Metastatic breast cancer previously untreated except in adjuvant setting
2. Exposure to anthracyclines limited
3. Treatment free interval more than 6 months
4. Normal ejection fraction
Participants - exclusion criteria History of cardiac disease
Anticipated start date 01/12/1996
Anticipated end date 05/11/1999
Status of trial Completed
Patient information material
Target number of participants 700
Interventions Epirubicin and paclitaxel/epirubicin and cyclophosphamide
Primary outcome measure(s) Progression free survival.
Secondary outcome measure(s) Overall survival, response, toxicity, quality of life (Fact-B Quality of Life, Questionnaire); and health economics (Cost and Resource Use Questionnaire).
Sources of funding Medical Research Council (UK)
Trial website
Publications 2005 results in http://www.ncbi.nlm.nih.gov/pubmed/16293863
Contact name Dr  Barbara  Uscinska
  Address MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Email
Sponsor Medical Research Council (MRC) (UK)
  Address 20 Park Crescent
  City/town London
  Zip/Postcode W1B 1AL
  Country United Kingdom
  Tel +44 (0)20 7636 5422
  Fax +44 (0)20 7436 6179
  Email clinical.trial@headoffice.mrc.ac.uk
  Sponsor website: http://www.mrc.ac.uk
Date applied 28/02/2001
Last edited 07/10/2009
Date ISRCTN assigned 28/02/2001
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2013 ISRCTN unless otherwise stated.